Date / Time
The goal of this activity is to educate ex-US gynecologic oncologists, medical oncologists, nursesand other healthcare professionals about the recent developments in the use of immunotherapy in the treatment of endometrial cancer and incorporating new data and new therapies into their patient treatment plans.
This educational program is intended for ex-US gynecolgoic oncologists, medical oncolgoists, nurses and other healthcare providers who care for patients with endometrial cancer.
Upon completion of this activity, participants should be able to:
- Evaluate current and emerging clinical trial data regarding new immunotherapy treatment options for patients with endometrial cancer
- Assess MSI and dMMR status as part of recommended molecular subtyping and genomic characterization of endometrial carcinomas at baseline and following recurrence
- Describe the role of immune checkpoint inhibitor-based therapy in endometrial cancer classified as microsatellite stable